NeoPhore Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$39.9M
- Investors
-
21
NeoPhore General Information
Description
Developer of novel small molecule therapies designed to treat cancer through stimulation of the immune system. The company's therapies target genetic mechanisms to create neoantigen which are known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.
Contact Information
Website
www.neophore.comCorporate Office
- 3rd Floor
- 1 Ashley Road, Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
Corporate Office
- 3rd Floor
- 1 Ashley Road, Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
NeoPhore Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 05-Jan-2024 | $39.9M | Completed | Generating Revenue | ||
| 5. Early Stage VC | 09-Mar-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 23-Jan-2020 | Completed | Generating Revenue | |||
| 3. Grant | 27-Apr-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 15-Nov-2017 | $3.95M | $3.95M | Completed | Generating Revenue | |
| 1. University Spin-Out | 09-May-2017 | Completed | Startup |
NeoPhore Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B3 Ordinary | ||||||||
| B2 Ordinary | ||||||||
| B1 Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | 131,241 | $0.012667 | $43.43 | $43.43 | 1x | $43.43 | 5.24% | |
| A Ordinary | 56,604 | $0.012667 | $33.57 | $33.57 | 1x | $33.57 | 2.26% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NeoPhore Comparisons
Industry
Financing
Details
NeoPhore Competitors (2)
One of NeoPhore’s 2 competitors is Autolus, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
NeoPhore Patents
NeoPhore Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202417501-D0 | Inhibitor compounds | Pending | 28-Nov-2024 | ||
| WO-2026115265-A1 | Inhibitor compounds | Pending | 28-Nov-2024 | ||
| AU-2024281784-A1 | (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses | Pending | 26-May-2023 | ||
| EP-4720038-A1 | (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses | Pending | 26-May-2023 | ||
| WO-2024246496-A1 | (hetero)aryl-carbonyl-heterobicyclic compounds as inhibitors of pms2 for cancer and degenerative illnesses | Inactive | 26-May-2023 | A61P21/02 |
NeoPhore Signals
NeoPhore Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3B Future Health Fund | Venture Capital | Minority | ||
| 4basebio | Corporation | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Cambridge Enterprise Ventures | Venture Capital | Minority |
NeoPhore FAQs
-
When was NeoPhore founded?
NeoPhore was founded in 2017.
-
Where is NeoPhore headquartered?
NeoPhore is headquartered in Altrincham, United Kingdom.
-
What is the size of NeoPhore?
NeoPhore has 20 total employees.
-
What industry is NeoPhore in?
NeoPhore’s primary industry is Drug Discovery.
-
Is NeoPhore a private or public company?
NeoPhore is a Private company.
-
What is the current valuation of NeoPhore?
The current valuation of NeoPhore is .
-
What is NeoPhore’s current revenue?
The current revenue for NeoPhore is .
-
How much funding has NeoPhore raised over time?
NeoPhore has raised $69.2M.
-
Who are NeoPhore’s investors?
3B Future Health Fund, 4basebio, Astellas Venture Management, Bristol-Myers Squibb, and Cambridge Enterprise Ventures are 5 of 21 investors who have invested in NeoPhore.
-
Who are NeoPhore’s competitors?
Autolus and Adaptimmune Therapeutics are competitors of NeoPhore.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process